Vector BioMed And Muni Seva Ashram Partner To Bring CAR-T Cell Therapy To Rural India

Patients expected to be treated in Q1 2026 at Gujarat's Kailash Cancer Hospital

US-based Vector BioMed, a purpose-driven contract vector development and manufacturing organization (CVDMO) focused on advancing access to cell and gene therapies, has announced a strategic partnership with Muni Seva Ashram's Kailash Cancer Hospital and Research Center (KCHRC) in Gujarat.

This collaboration positions Vector BioMed as the preferred and exclusive CVDMO partner for KCHRC's cell therapy programme, helping expand affordable CAR-T cancer treatment to underserved populations.

The partnership began in June 2024 after more than a year of due diligence, site visits, and technical evaluations led by KCHRC's leadership. The hospital is expected to begin treating its first patients with autologous CAR-T cell therapy in Q1 2026, making it the first site in Gujarat and one of the first in India to deliver advanced treatments outside of a major metropolitan area.

Vector BioMed supplies rapid CAR-T formats of prebuilt CARs and validated processes, including a cell manufacturing process ready anti-CD19 CAR-T solution and other IND-ready product options for the production of autologous CAR-T therapies. Constructed to streamline development for hospitals and researchers, this introduces speed, consistency, and a dramatic improvement to the global standard of care for cancer treatment.

Located in rural Gujarat, KCHRC serves over 70,000 outpatients annually, offering reduced (donor supported)- or no-cost care to more than 60% of its patients. The hospital is part of Muni Seva Ashram, a nonprofit institution founded to provide equitable healthcare to India's most vulnerable communities.

Vector BioMed is supporting the rollout with its LENTIVERSE™ system, a true platform solution designed for flexibility, affordability, and scalability, especially for low- and middle-income countries (LMICs).